Multiple Myeloma Face-Off: Karmanos Cancer Institute vs Cleveland Clinic

home / face-off / multiple-myeloma-face-off-karmanos-cancer-institute-vs-cleveland-clinic

Two teams from Karmanos Cancer Institute and Cleveland Clinic debate and discuss recent data in the multiple myeloma treatment landscape.

The host of Cancer Network's Face-Off program shown with an introductory slide

EP. 1: Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 13th 2023

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

EP. 2: ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 13th 2023

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

Andrew Kin, MD, an expert on multiple myeloma

EP. 3: Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 20th 2023

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Jack Khouri, MD, an expert on multiple myeloma

EP. 4: CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 20th 2023

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

EP. 5: Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 27th 2023

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

EP. 6: Outcomes After Biochemical or Clinical Progression in Patients with MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
October 27th 2023

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

EP. 7: Cross Q&A: Retrospective Study of Patients With MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 3rd 2023

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

EP. 8: REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 3rd 2023

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

EP. 9: Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 10th 2023

Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.

Craig Cole, MD, an expert on multiple myeloma, presenting slides

EP. 10: DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 10th 2023

Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Treatment Updates and Key Highlights in Multiple Myeloma and CML

EP. 11: Treatment Updates and Key Highlights in Multiple Myeloma and CML

ONCOLOGY Staff
November 13th 2023

Karmanos Cancer Institute and Cleveland Clinic gave presentations regarding treatment of multiple myeloma and chronic myeloid leukemia in the latest Face Off.

Craig Cole, MD, an expert on multiple myeloma, presenting slides

EP. 12: Cross Q&A: Role of Belantamab Mafodotin in MM

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH
November 17th 2023

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.